|Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension.|
|PMID: 20100989 Owner: NLM Status: MEDLINE|
|Calcitonin gene-related peptide (CGRP) is a powerful vasodilator that interacts with the autonomic nervous system. A subunit of the CGRP receptor complex, receptor activity-modifying protein 1 (RAMP1), is required for trafficking of the receptor to the cell surface and high-affinity binding to CGRP. We hypothesized that upregulation of RAMP1 would favorably enhance autonomic regulation and attenuate hypertension. Blood pressure, heart rate, and locomotor activity were measured by radiotelemetry in transgenic mice with ubiquitous expression of human RAMP1 (hRAMP1) and littermate controls. Compared with control mice, hRAMP1 mice exhibited similar mean arterial pressure, a lower mean heart rate, increased heart rate variability, reduced blood pressure variability, and increased baroreflex sensitivity (2.83+/-0.20 versus 1.49+/-0.10 ms/mm Hg in controls; P<0.05). In control mice, infusion of angiotensin II (Ang-II) increased mean arterial pressure from 118+/-2 mm Hg to 153+/-4 and 174+/-6 mm Hg after 7 and 14 days of infusion, respectively (P<0.05). In contrast, Ang-II hypertension was markedly attenuated in hRAMP1 mice with corresponding values of mean arterial pressure of 111+/-2, 119+/-2, and 132+/-3 mm Hg. Ang-II induced decreases in baroreflex sensitivity and heart rate variability, and increases in blood pressure variability observed in control mice were also abrogated or reversed in hRAMP1 mice (P<0.05). Moreover, during the Ang-II infusion, the pressor response to the CGRP receptor antagonist CGRP(8-37) was significantly greater (P<0.05) in hRAMP1 mice (+30+/-2 mm Hg) than in control mice (+19+/-2 mm Hg), confirming a significantly greater antihypertensive action of endogenous CGRP in hRAMP1 mice. We conclude that RAMP1 overexpression attenuates Ang-II-induced hypertension and induces a protective change in cardiovascular autonomic regulation.|
|Rasna Sabharwal; Zhongming Zhang; Yongjun Lu; Francois M Abboud; Andrew F Russo; Mark W Chapleau|
Related Documents :
|12699509 - Circulatory effects of angiotensin ii during anaesthesia, evaluated by real-time spectr...
6328239 - Interrelationship between subpressor effects of vasopressin and other vasoactive hormon...
7608279 - Intravenous administration of l-arginine inhibits angiotensin-converting enzyme in humans.
6329559 - Diminished sympathetic responsiveness in nephrectomized rats-role of the renin angioten...
7864169 - Intravertebral ang ii effects on plasma renin and na excretion in dogs at constant rena...
9869009 - Dissociation of blood pressure reduction from end-organ damage in tgr(mren2)27 transgen...
21092009 - The effects of hypohydration on central venous pressure and splenic volume in adult hor...
893679 - Evidence for cardiomyopathy in familial diabetes mellitus.
9701439 - Introduction to a new inspiratory threshold loading device.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. Date: 2010-01-25|
|Title: Hypertension Volume: 55 ISSN: 1524-4563 ISO Abbreviation: Hypertension Publication Date: 2010 Mar|
|Created Date: 2010-02-19 Completed Date: 2010-03-18 Revised Date: 2014-09-14|
Medline Journal Info:
|Nlm Unique ID: 7906255 Medline TA: Hypertension Country: United States|
|Languages: eng Pagination: 627-35 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Angiotensin II Type 1 Receptor Blockers / pharmacology
Autonomic Nervous System Diseases / physiopathology
Baroreflex / physiology*
Blood Pressure / physiology*
Calcitonin Gene-Related Peptide / genetics
Gene Expression / physiology
Heart Rate / physiology
Hypertension / chemically induced, drug therapy, physiopathology*
Intracellular Signaling Peptides and Proteins / genetics*, metabolism*
Losartan / pharmacology
Membrane Proteins / genetics*, metabolism*
Parasympathetic Nervous System / physiology
Receptor Activity-Modifying Protein 1
Receptor Activity-Modifying Proteins
Receptor, Angiotensin, Type 1 / genetics
Vasoconstrictor Agents / pharmacology
|DE016511/DE/NIDCR NIH HHS; HL14388/HL/NHLBI NIH HHS; P01 HL014388-36A1/HL/NHLBI NIH HHS; R01 DE016511/DE/NIDCR NIH HHS; R01 DE016511-17S1/DE/NIDCR NIH HHS|
|0/Angiotensin II Type 1 Receptor Blockers; 0/Intracellular Signaling Peptides and Proteins; 0/Membrane Proteins; 0/RAMP1 protein, human; 0/Ramp1 protein, mouse; 0/Receptor Activity-Modifying Protein 1; 0/Receptor Activity-Modifying Proteins; 0/Receptor, Angiotensin, Type 1; 0/Vasoconstrictor Agents; 11128-99-7/Angiotensin II; 83652-28-2/Calcitonin Gene-Related Peptide; JMS50MPO89/Losartan|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Burden of cardiovascular risk factors, subclinical atherosclerosis, and incident cardiovascular even...
Next Document: Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic conseque...